• Singular Research has released an updated report on Hillcrest Energy Technologies detailing the many accomplishments of the company during the 2H 2022
• Hillcrest completed its first working prototype of its ZVS inverter, which has attracted the attention of majors in the electric mobility, including Hercules Electric Mobility and a Tier 1 automotive supplier
• Singular estimates the innovation may lead to revenue for Hillcrest later this year, rising to $10.6 million in 2024, a figure used to calculate a valuation of 20 cents per share, up 177% from the current price

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean-technology company developing transformative power conversion technologies and control system solutions for next-generation EVs and electrical systems, was the subject of an updated report by Singular Research released on January 4, 2023. In a report in August, Singular speculated on the prospects of Hillcrest’s “potential breakthrough” inverter technology and how it could attract the attention of majors in the automotive industry (https://ibn.fm/qPMJT). The January report detailed the partnerships that have already come to fruition as Hillcrest continues to hit critical milestones, underscoring Singular reiterating its Buy–Venture rating and a $0.20 price target from current level of $0.0722. Singular covered the extremely productive second half of the year for Hillcrest, which was highlighted by several substantial accomplishments, including completion of the first commercial prototype of their 250-kilowatt, 800-volt Zero Voltage Switching (“ZVS”) inverter. The prototype and tech undergirded the signing of a Memorandum of Understanding with Hercules Electric Mobility, a major step towards commercialization. Per the MOU, the companies are collaborating to build and test an electric powertrain system featuring a Hillcrest 250kW, 800V inverter that has been optimized for a Hercules powertrain. Early in 2022, Coach Marine Group chose the Hercules 200kW e-drive system as the electric propulsion system for its Coach and Xcursion branded electric pontoon boats. Coach plans to manufacture up to 1,500 electric pontoon boats annually using the Hercules system, which could have a meaningful impact on Hillcrest. Singular sees the potential for this relationship to lead to monetization of Hillcrest technology later this year. To the point of revenue, Singular posits Hillcrest to realize at least $200 per unit (a conservative estimate of ~2-4% of the total cost of a high-end inverter), which Singular models to approximately $750,000 in revenue for the fourth quarter of 2023. Looking further ahead, Singular projects revenue to increase quarter-over-quarter to result in about $10.6 million in revenue for 2024. Singular forecasts Hillcrest to be EBITDA positive in the second quarter of 2024. Hercules wasn’t the only catalyst covered for commercialization efforts. In October, Hillcrest disclosed a partnership with an anonymous global Tier 1 automotive supplier for the purpose of integrating an optimized version of Hillcrest’s 250kW, 800V ZVS inverter technology into a new powertrain system for the auto markets. Throughout the year, the partners will test different configurations with the goal of commercializing a nominal 350kW product utilizing the benefits of Hillcrest’s technology. To fund its continued development, Hillcrest recently closed a temporary warrant exercise program and first tranche of a non-brokered private placement, raising $1.87 million. Other topics covered in the report included the addition of James Bolen as Chief Commercialization Officer, adding 30+ years’ executive-level experience to the team, and a revenue multiple analysis valuation. Using a discounted rate, Singular values Hillcrest at 20 cents per share, implying a 177% upside from the price per share at the time of the report. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

Professionals and executives from the pharma, medical device, biotech, and life science medical fields, are invited to attend the premiere Clinical Research in Latin America Summit by DGE, streaming online on February 9-10th, 2023. Latin America is a crucial growth zone for the future of clinical research and has numerous ethnic groups, meaning greater representation of diverse groups in clinical trials. The challenges lie in areas like logistics, resources, and publications. Get all your questions answered and gain valuable guidance from a diverse community of experts at the Clinical Research in Latin America Summit by DGE.The event is organized by Dynamic Global Events (“DGE”), a leading life science B2B event organizing company. DGE events is devoted to offering a viable forum for discussion and interaction with the medical industry. Timely and important topics are discussed by experts on DGE’s platforms, with an immersive audience, and live-streamed on. The events are attended by specialists of global acclaim with profound experience and knowledge in their respective fields.

At the Clinical Research In Latin America Summit, industry leaders and experts will offer their valuable advice on successfully employing strategies to conduct clinical research and execute viable clinical trials throughout the region. In the evolving landscape, it is critical to consider demographics covering diverse areas like Latin America in clinical trials—keeping these population-concentrated areas in mind, it is important to design futuristic strategies in clinical trials. Industry-leading experts will discuss ways to overcome hurdles to achieve greater patient retention and enrollment in Latin America.

Important issues to be discussed at the event:

• Clarifying the status of the current landscape and that of the highly skilled HCPs
• Understanding how to explore the different multiple regulatory frameworks
• Better engagement across different sectors of regional cross-collaborations
• Embracing robust medical strategies to reduce the gaps in patient knowledge
• Ways to perform the task of eradicating hurdles of local research capacity
• Learning novel ideas to make up for the low volume of publications

Join leading experts in the biopharma sector as they unveil actionable strategies for study coordination, site interaction, patient enrollment, partnership design, regulatory compliance, and much more. This DGE event aims to build a robust research pipeline through improved collaboration strategies, renewed public outreach, and a commitment to diversity.

To learn more, please visit https://ibn.fm/xYEq8

Connect with TA pros and HR leaders at the Talent Acquisition Week being held this January in Southern California, as industry leaders deliver keynote speakers and hold discussions on the future of recruiting. For the last 10 years, the Social Recruiting Strategies Conference (#SRSC) has focused on providing TA pros and HR managers the trending HR practices, global recruiting marketing trends, candidate engagement, plus related tools and technologies through practitioner-to-practitioner sessions, panel discussions and case studies. This year, SRSC returns as a flagship event of the Talent Acquisition Week being held in January 31 to February 2, 2023. The larger-than-life event will showcase 3 talent attraction events live and in person — SRSC, Talent Sourcing Strategies Summit, and Employer Branding Strategies Conference. These power-packed shows will bring together eminent industry leaders and HR stalwarts on a common platform, offering networking and talent acquisition. In addition, registered TA Week attendees are eligible to enter a talent attraction video for the event’s showcase contest. They will also have access to view video submissions and vote on the videos of their choice. The winner will be announced on stage at TA Week and receive a full-year Amplify VMS license with unlimited users and unlimited video creation. Why attend Talent Acquisition Week?

• TA pros can avail this tremendous opportunity to access the best industry practices for employer branding, identifying and recruiting, all under one roof
• Get valuable insights from peers and influencers on candidate messaging and engagement
• Tips on sourcing, employer branding, social recruiting as well as in-person networking with TA personnel
• Understand ways to improve candidates’ recruiting and retention experiences
• Learn effective information from fellow talent attraction pros that you can apply to your strategy now
• Hire and retain the best talent to derive the maximum from your TA strategy

The agenda of the #TAW is extensive with conferences and workshops on achieving recruiting and retention success. Attendees will learn the best hiring techniques and effective global talent strategies. Workshops will also be conducted on building employer brands. Other conference topics include discussion on winning the TA trifecta and improving recruiting experiences. Keynote panel discussions include ways o attract and hire top talent. The Expo floor offers a robust forum where attendees can explore more interesting topics and avenues. To learn more, please visit https://ibn.fm/iBAai

Professionals and executives from the biopharma, health organizations, CROs, Digital Solutions, Policy Developers, and Medical Device Companies, are invited to attend the Health Equity In Clinical Trials Congress being held in Boston, February 22-23, 2023. Participants will get access to a wide spectrum of healthcare opportunities and the chance to meet and connect with veterans of the industry. In the two main event days, 25+ leading industry speakers will gather on this forum to share their valuable insights in 5 keynote sessions, and will discuss tactful approaches to drive meaningful change for underrepresented communities through meaningful cross-industry networks and scaling equity initiatives. Attendees will get deeper insights from these equity change-makers to more fully understand strategies for expanding diversity, equity and inclusion programs, through industry action and technology. The opening panel discussion topic will be on biopharma advancements for inclusive investigations and health equity programs, conducted by leading clinical trial experts in the industry. Why attend the Clinical Trials Congress?

• Meet peers, advocates and industry experts and grow your business network
• Learn and understand from case studies, success stories, and experiences shared by your peers and leaders
• Make a list of all pointers that form a foundation for your business; strategies, roadmaps, and other insights offered by the stalwarts at the congress
• Attending the congress is a business investment that will also contribute to the personal growth of professionals and executives by increasing their knowledge base

Those interested in pitching their business or services at the conference can get curated packages that range from presenting their expertise on the main stage to hosting a private dinner. Interested candidates can partner with the event organizers at Kisaco Research to showcase their brand and make valuable new connections. There are 3 main categories: Thought Leadership, Branding & Networking. If you would like to register a team of 3 or more, please email events@kisacoresearch.com for a discount coupon code before registering. To learn more, please visit https://ibn.fm/8tTzM

• Google will change its requirements for product ads on January 20, 2023, to allow the promotion of FDA-approved pharmaceuticals containing CBD and topical hemp-derived CBD products in California, Colorado, and Puerto Rico
• Non-FDA-approved CBD topicals will require certification from LegitScript, which will test THC compliance and review the third-party Certificate of Analysis of each product to be promoted
• With the growing acceptance of cannabis, REZYFi is positioned in the financial industry as one of the first cannabis mortgage bankers in the United States

In the United States, cannabis-related products are growing in acceptance, even in mainstream media. A recent announcement from Google advises that the company will update its Dangerous Products and Services and Healthcare and Medicines Google Ads policies on January 20, 2023. Google will allow for the promotion of FDA-approved pharmaceuticals containing cannabidiol (“CBD”) and topical, hemp-derived CBD products with a tetrahydrocannabinol (“THC”) content of 0.3% or less in California, Colorado, and Puerto Rico. Non-FDA-approved topicals will require verification through LegitScript. Google will continue to disallow ads promoting other CBD-based products, including supplements, food additives, and inhalants (https://ibn.fm/M9LvO). For non-FDA-approved CBD topicals, LegitScript’s certification will require that products sought to be advertised: (1) provide samples for compliance testing of legal THC limits, and (2) provide a third-party Certificate of Analysis. LegitScript charges a fee for processing and monitoring applicants. However, through March 31, 2023, the company is offering a waiver of application fees with promo code “CBDPRODapp” for product certification (https://ibn.fm/OFs69). Since 2016, when California legalized cannabis, the state has shown a growing acceptance – which has been working its way across the country. According to Pew Research Center, nearly 90% of adults in the US favor cannabis, with 59% showing favor for recreational and medical use and 30% showing favor for medicinal use only (https://ibn.fm/bUevz). Not all industries have embraced the acceptance of cannabis, though, with many traditional financial institutions still reticent to serve the state-licensed cannabis industry. Disrupting the financial industry and favoring cannabis-related companies is REZYFi, a growth mortgage origination and specialized financing company in the United States. REZYFi originates, structures, and invests in first mortgage loans and alternative structured financings secured by commercial real estate properties. The company targets markets that include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing. REZYFi works through two wholly-owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent, and servicing operation. Through these subsidiaries, REZYFi plans to use its corporate strengths – experience, a network of independent brokers, and proprietary technology – to provide an essential source of growth within the cannabis industry, positioning itself as one of the first cannabis mortgage bankers in the United States. Combined, the medical and recreational use of cannabis are expected to reach a market value of $33 billion by the end of 2022, with retail cannabis sales projected to reach $52.6 billion by 2026 (https://ibn.fm/rLtya). The growth is attributed to more state voters accepting cannabis for recreational and medicinal use. The growing acceptance of cannabis for medicinal and recreational use is driving markets in various industries, creating a call for services, including financing options – which REZYFi is uniquely positioned to answer. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• MetAlert recently released its yearend shareholder update letter, covering the past year’s progress, and associated plans for 2023, all focused on helping to monitor the safety and location of dementia patients and other vulnerable individuals
• Coupled with concerns about patients with Alzheimer’s disease or other brain conditions that may lead toward risks of them wandering, becoming lost or disoriented, or falling, the situation demonstrates an opportunity for remote monitoring of patients’ whereabouts
• To meet the need, MetAlert developed a pioneering wearable GPS-enabled tracking device a decade ago that unobtrusively slips into wearers’ shoes
• The company has since expanded the device’s capabilities in keeping with developments in remote patient monitoring technology and insurance company recognition to monitor falls, wandering, and other health concerns

Following a year of wearable technology advances together with a rebranding and restructuring drive, medical patient location device developer MetAlert (OTC: MLRT) is working with shareholders to demonstrate the “significant potential” for market value found in MetAlert’s GPS two-way tracking technologies.

MetAlert developed its patented flagship GPS SmartSole shoe insoles a decade ago as a solution for those at risk of wandering or becoming lost or disoriented due to Alzheimer’s disease, dementia, autism, or traumatic brain injury.

The SmartSole later also found utility as a safeguard for people at risk of kidnapping, such as government employees, journalists and corporate executives. But during the early months of the COVID pandemic, the company noted an additional opportunity as a remote health solution to help patients avoid having to visit crowded doctor clinics when possible, thereby avoiding health risks from other patients that might be more dangerous than the condition being treated.

The result, the expanded capabilities of the SmartSole plus(R), provides a means of establishing a Bluetooth connection with a wearable “hub” for collecting health data in real-time wherever users may be and communicating that information to medical providers.

“Converging factors, such as wide adoption of telehealth and related third-party payer approval, the ability for wireless networks to transmit large amounts of data in nanoseconds, and advancements in artificial intelligence, led us to make the decision to expand our tracking and monitoring platform,” CEO and Founder Patrick Bertagna stated in a Jan. 5 letter to the shareholders (https://ibn.fm/jxUCt). “MetAlert provides a complete indoor/outdoor remote patient monitoring biometric health and wellness solution, with potential for insurance reimbursement and possibly, a long-term predictive A.I. big data play.”

During 2022, the company also changed its name and ticker symbol, plus conducted a reverse split, and prepared for further developments in 2023, including rolling out the hub to the public along with a small GPS tracker shorter than a credit card that will provide the same functionality as the insoles with a longer (two weeks) battery life between charging.

During the past year, MetAlert also eliminated its variable convertible debt and signed a letter of intent (“LOI”) with Norway-based Sensio Group to begin marketing and distributing the company’s new 3D Infrared indoor remote patient monitoring system called RoomMate, which provides fall detection to caregivers.

MetAlert also engaged Joseph Gunnar & Co., LLC as its financial adviser to help the company prepare for uplisting to a national stock exchange and exploring acquisitions that may accelerate MetAlert’s growth.

“We are now taking dramatic steps to align the public-facing (stock) part of the company with the operations and vision of the company,” Bertagna wrote. “Strategic acquisitions, expanding our products and services, and increasing our revenues per user (“RPU”), should help set us on a path toward continued success in the coming months and years. Moreover, aligning with new technologies could open possibilities for crucial data analysis that has the potential to revolutionize how we conduct and manage healthcare worldwide.”

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

• Direct-sales environment is evolving as younger generations explore opportunity
• Changing consumer behaviors, a tough regulatory environment and lingering supply chain struggles are industry challenges
• SHRG’s primary growth strategy is built on focused innovation and creativity positioned to capture profitable market share

The beginning of a new year is an ideal time to reflect on what the direct-sales industry may look like this year, and companies such as Sharing Services Global (OTCQB: SHRG) are likely to benefit as the space appears set to see significant growth. “To say direct selling is in a time of transition would be an understatement,” said a recent Direct Selling News article (https://nnw.fm/W6pFi). (https://ibn.fm/peKaf). “The environment is evolving as younger generations explore the opportunity. And the post-pandemic trends of quiet quitting and the desire for more workplace flexibility continue to shape where, how and why people of all ages choose to earn a living. Everyone working in the industry is aware of the decisions, pivots and pain points we have ahead of us as executives, as companies and as a channel.” The article explained that Direct Selling News reached out to 75 C-level executives representing a combined $43 billion in revenue to gather feedback regarding the challenges and opportunities facing the channel. “The topics most often mentioned should come as no surprise,” the article observed. “Concerns like changing consumer behaviors and a tough regulatory environment as well as lingering supply chain struggles, Amazon and eCommerce strategies and field fatigue were mentioned often. Mergers, acquisitions and consolidations also continue to be a popular topic of conversation.” Staying on top of the trends and looking for solutions to the challenges in the direct-selling space is a priorty for Sharing Services, a company dedicated to building shareholder value by developing or acquiring businesses, products and technologies in the direct-selling industry as well as other industries that augment its product and services portfolio, business competencies, and geographic reach (https://nnw.fm/CDMbO). (https://ibn.fm/qwyNK). “Our primary growth strategy is built on focused innovation and creativity positioned to capture profitable market share of diverse business models,” the company website declares. The company operates with a mission designed to “increase shareholder value by adhering to standards of excellence that optimize the value of the people involved, supply chain, and channel of distribution, achieving optimal customer satisfaction through every subsidiary and partnership interest.” SHRG currently has some form of controlling interest in My Travel Ventures(TM), which makes it easy to plan, book and save on travel adventures near and far; MojiLife, which offers a flagship product to scent homes and vehicles that features the latest in innovative technology and design (https://nnw.fm/ZvYVV); (https://ibn.fm/mSu9d); and the Happy Co., which offers functional beverages, capsules, patches, and creams that elevate mood, boost energy, reduce stress, enhance sleep, increase muscles, minimize fat, tighten skin, and make users look, feel and perform like a younger person (https://ibn.fm/XyAbN). The company’s combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. For more information, visit the company’s websites at www.SHRGInc.com, www.MyTravelventures.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• SideChannel is on a mission to make cybersecurity simple and accessible, mainly targeting small and mid-sized organizations which often fall victim to hackers given their insufficient budgets to invest in an on-site Chief Information Security Officer (“CISO”)
• With hacking and ransomware attacks on the rise, crypto operations, as well as other small and mid-sized organizations, are at risk of falling victim, resulting in a disruption and potentially damaging their operations
• While code audits are still essential, SideChannel’s unique approach to the problem (creating top-tier cybersecurity programs) guarantees both asset and data protection for these enterprises

Within the first three months of 2022, hackers had stolen over $1.3 billion from exchanges, platforms, and private entities, with the victims disproportionately in Decentralized Finance (“DeFi”) and crypto. In 2021, over $3.2 billion worth of cryptocurrency was stolen, and it is projected that the cybersecurity risks to crypto operations will only increase as time progresses (https://ibn.fm/ef8ga). SideChannel (OTCQB: SDCH), a company on a mission to make cybersecurity simple and accessible, is looking to remedy the situation, mainly by targeting small and mid-sized organizations which often fall victim to hackers given their insufficient budgets to invest in the expertise of an experienced Chief Information Security Officer (“CISO”). By matching companies with an expert virtual CISO (“vCISO”), SideChannel helps them to improve their cybersecurity and move their mission forward. Furthermore, it enables these enterprises to assess cyber risk and ensure cybersecurity compliance without spending sums that could potentially jeopardize their financial assets (https://ibn.fm/BXyqb). SideChannel’s tailor-made services for crypto and digital asset supply chain cut across exchanges, wallets, mining operations, construction, and power, with the guarantee of defending current security investments while integrating new tools and consumer data protection without disruption. The company also promises a proactive defense that stops threats before they get to data while at the same time reducing security costs by aligning security strategy to overall business goals. This approach has allowed SideChannel’s operations to scale its operations, covering crypto trading platforms, producers and brokers, hedge funds, mining operations, exchanges, and identities, with a huge market opportunity that continues to grow with every passing day. With hacking and ransomware attacks on the rise, small and mid-sized organizations and crypto exchanges risk falling victim and disrupting their operations, which is costly and potentially damaging to their operations. Threats that include, but are not limited to, commodity exploits, distributed denial of service attacks (“DDoS”), and code corruption have the potential to halt entire business operations, especially in the crypto and digital asset sectors (https://ibn.fm/u4b4f). However, SideChannel seeks to make solutions more accessible and affordable, ultimately becoming an integral partner to small and mid-sized enterprises in this sector. SideChannel’s management acknowledges that code audits can help with reducing the risk of a successful hack. However, with Chainanalysis estimating that nearly 30% of code exploits occurred on platforms audited within the past year, coupled with a surprising 73% of flash loan attacks, there is a need for a more robust and practical approach to maintaining the integrity of these systems. This highlights SideChannel’s unique approach to the problem- creating top-tier cybersecurity programs for small businesses to help them protect their assets and data. “As companies invest more in cyber resilience, criminals are finding sophisticated pathways around their defenses, meaning the most dangerous weaknesses are the invisible ones,” noted Dustin Warren, the senior security researcher at cybersecurity company, SpyCloud (https://ibn.fm/E9BC8). So far, SideChannel has attracted over 20 virtual CISOs to serve across industries, including fintech, biotech, healthcare, manufacturing, legal, defense, crypto, and technology services. With the global cybersecurity market projected to grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, the company is readying itself to capitalize on this growth and is on track to do so (https://ibn.fm/LxfM2). By supporting the crypto and digital asset supply chain to include wallets, identities, mining operations, exchanges, power, and identities, SideChannel is aiding with the proliferation of crypto, and the growth of the sector, which is estimated to post a CAGR of 12.2% from 2022 to 2030. This has facilitated its growth thus far, having posted a 71% year-over-year growth (https://ibn.fm/AbbDN), which Brian Haugli, its CEO, termed as a “demonstration of our [the company’s] continued strength and position in the market across both product and service delivery.” For more information, visit the company’s website at www.SideChannel.com. NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Cerberus believes successful cybersecurity must be woven into an organization’s fabric, transforming its culture
• While cybersecurity has become a well-known topic, surprisingly few companies are doing anything about it
• Every 11 seconds, someone is targeted or hacked, and the weakest link inside a company is people who aren’t prepared, says CISO CEO

The idea that “cybersecurity is a culture, not a product” has never been more relevant or profound, says podcast host Ted Jenkin, who chatted with Cerberus Cyber Sentinel (NASDAQ: CISO) CEO David Jemmett during a recent episode of “The Shrimp Tank” (https://ibn.fm/o4CTg). Cerberus has trademarked that phrase and operates on the principle that successful cybersecurity is more than amassing a list of vendors and varied technologies; it must be woven into the fabric of an organization, encompassing and transforming that organization’s culture.

“When I saw their slogan that cybersecurity is a culture not a product, I think there probably couldn’t have been a more opportune time to interview David today because that really encapsulates what is happening today in America,” said Jenkin. “Whether you just have a few PCs in your house, or you’ve got a company of thousands of employees, today the question is: Are you more susceptible to a physical attack, or are you more susceptible to a cyberattack? And we’re seeing [cyberattacks] happen every single day.”

During the interview, Jemmett noted that, although cybersecurity is often discussed and has become a well-known subject in today’s business world, surprisingly few companies are doing enough about this very real threat.  “A lot of folks are not addressing [cybersecurity]… They don’t want to know what they don’t know because they’re going to have to fix it, which costs money,” Jemmett said. “Cybersecurity is an actual concern that people should be aware of, and training and understanding what really happens is important.”

Jemmett also pointed out that “every 11 seconds, someone is being targeted or hacked, and the weakest link inside a company is the people not being prepared. The reason we trademarked ‘Cybersecurity is a culture, not a product’ is because it’s from the top down. If leadership doesn’t understand, it becomes a black hole. How can you address something you’re not understanding?” This is a key point, given that many organizations have worked to educate their C-suites about the importance of cybersecurity but have not helped them deepen their technical knowledge.

As an industry thought leader, David Jemmett wants leadership teams to understand more than just the importance of cybersecurity. He knows that C-suites and boards need to be cyber-literate enough to determine how things work and which technical and process investments matter most and in what order. Otherwise, it’s easy to simply invest the latest technology and assume their problems are solved.

Additionally, Jemmett observed that traditional IT is different than cybersecurity. “IT puts systems together and tries to secure it after they’ve designed it. We think like hackers, with security by design… [Companies] should start any kind of application or implementation of services by understanding how to secure it first, but a lot of people don’t have that understanding. It pays to go get someone to help them through that process, but make sure they’re professionals. If you get in a car accident and go to the emergency room, you don’t want a dermatologist or general practitioner working on you; you want someone who has years of experience.”

Cerberus brings many years of experience to the table. The company’s leadership team has decades of success in a range of sectors, including executive management and technology experience in cybersecurity consulting services; securely engineering, building, revamping and managing global networks and data centers; cybersecurity application and implementation across military, financial services and professional services organizations; cyber force development; cyber defense operations; and cybersecurity advisement.

The company is widely recognized as a managed cybersecurity and compliance provider. Today, Cerberus is expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilizes the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations.

For more information, visit the company’s website at www.CerberusSentinel.com.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

• Silo Pharma recently provided an update on an ongoing study delving into the potential use of SPU-21 joint homing peptides as an alternative treatment for rheumatoid arthritis
• The study, which is being carried out in conjunction with the University of Maryland, Baltimore, has resulted in positive initial results
• Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently revealed the positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. The results come after the biopharmaceutical company initiated a pilot study on its novel joint homing peptides targeting rheumatoid arthritis in late November, specifically looking into the binding affinity of the peptide in healthy human and RA synovial tissue.

At the time, Eric Weisblum, Chief Executive Officer of Silo Pharma explained the rationale underpinning the study, “SPU-21 was shown to inhibit arthritic progression in a preclinical animal model, so we are proceeding to advance our research into human synovial tissue, where we will first assess binding affinity.  Positive data from this important study could support further research into the interaction of our joint homing peptide as a potential therapy for autoimmune disorders such as rheumatoid arthritis and inflammation.”

Rheumatoid arthritis is among the most common autoimmune diseases in the U.S., affecting approximately 1.5 Americans.  A 2022 report published by Precedence Research revealed that the global rheumatoid arthritis drugs market was expected to reach $70 billion by 2030, growing at a compound annual growth rate of 1.7% (https://ibn.fm/S8bqi).

Although historically treated using DMARDs (disease-modifying antirheumatic drugs) or steroids, Silo Pharma has sought to advance the use of liposomal homing peptides as an alternative treatment for rheumatoid arthritis, with a positive test result from the ongoing study potentially acting as justification for further investigation.

Silo Pharma provided an update on the ongoing study as of December 30, 2022. During the study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis drug versus the drug alone. The drug used in the study was dexamethasone (“DEX”), a corticosteroid used for its anti-inflammatory and immunosuppressant effects. Earlier results of the same study successfully demonstrated that the subcutaneous (“SC”) route of liposomal administration (small needle injection into shallow soft tissue just under the layer of skin) was-suited for use in targeted drug delivery of anti-arthritic agents (https://ibn.fm/h5fq6).

“We believe that the positive results of these latest tests show that our peptide with DEX given subcutaneously was effective in controlling arthritis progression.  The effect of lipo-DEX was superior to that of DEX alone when both were administered via the SC route,” elaborated Eric Weisblum. “Since patients widely prefer SC administration over intravenous (‘IV’) infusion for multiple reasons, we believe the superiority and practicality of our liposomal joint homing peptide bode well for broad market potential. Meanwhile, we continue to explore other novel therapeutics for optimal pairing with SPU-21, targeting rheumatoid arthritis as our initial indication.”

Originally founded in 2010, Silo Pharma has rapidly earned a reputation in recent years for its ground-breaking research into conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Whilst promising in nature, the company’s study into joint-homing peptides, which it is carrying out in conjunction with the University of Maryland, Baltimore, is just one of a multitude of promising initiatives Silo Pharma is currently pursuing. Other projects also include a study focused around assessing the effect of psilocybin on inflammation being carried out with the University of California, San Francisco (“UCSF”) as well as an agreement with Columbia University, with both entities jointly exploring the use of prophylactic treatment for stress-induced disorders and PTSD (https://ibn.fm/YWacO).

For more information, visit the company’s website at www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO